4DMT to Participate in Upcoming Investor Conferences
Key Highlights
- ➤4DMT will present at seven healthcare investor conferences from November 10 through December 10, 2026
- ➤4D-150 is in Phase 3 development for wet age-related macular degeneration and diabetic macular edema
- ➤4D-710 demonstrated CFTR transgene delivery and expression in cystic fibrosis patients after aerosol delivery
EMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in November and December: * Guggenheim 3(rd) Annual Healthcare Innovation Conference: Tuesday, November 10, 2026; Fireside chat at 4:30 p.m. ET * Stifel 2026 Healthcare Conference: Wednesday, November 11, 2026; Fireside chat at 8:00 a.m. ET * Jefferies Global Healthcare Conference in London: Monday, November 16, 2026; Fireside chat at 1:30 p.m. GMT * 9(th) Annual Evercore Healthcare Conference: Tuesday, December 1, 2026; Fireside chat at 8:45 a.m. ET * Citi Global Healthcare Conference 2026: Wednesday, December 2, 2026; Fireside chat at 3:00 p.m. ET * Piper Sandler 38(th) Annual Healthcare Conference: Thursday, December 3, 2026; Fireside chat at 8:30 a.m. ET * Barclays Virtual Ophthalmology Day: Thursday, December 10, 2026; Fireside chat at 10:30 a.m. ET Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
Get started
Create a free account to read the full story.